May 04, 2009
You are receiving this email because you opted in for the newsletter.
Telcagepant Update
Sorry to bother you again but I just had an update on the status of Telcagepant. This comes straight from the company Merke, as one of the research directors met with us today at Dent Institute.The issue of elevated liver enzymes was seen in a trial where the drug was used daily as a preventative. Merke sponsored the trial, but has the position that this drug is better suited for abortive treatment only.
None the less, they are re-examining the abortive therapy trials and reviewing them. They are planning to go ahead with Phase 3 trials of the drug, but only for abortive therapy.
I hope you are doing well...
Here's To Headache Free Days
Take care..
Mary Kay Betz, MS RPA-C
Physician Assistant
For information on how my website was built visit Site Build It.
